1. Home
  2. ARVN

as 05-24-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
.
-
-
%

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

Founded: 2015 Country:
United States
United States
Employees: 445 City: NEW HAVEN
Market Cap: 2.4B IPO Year: 2018
Target Price: $62.94 AVG Volume (30 days): 730.9K
Analyst Decision: Strong Buy Number of Analysts: 16
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -6.05 EPS Growth: N/A
52 Week Low/High: $13.57 - $53.08 Next Earning Date: 05-07-2024
Revenue: $71,300,000 Revenue Growth: -48.07%
Revenue Growth (this year): 107.46% Revenue Growth (next year): 30.22%

ARVN Daily Stock ML Predictions

Stock Insider Trading Activity of Arvinas Inc. (ARVN)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Houston John G ARVN President and CEO Feb 23 '24 Sell $47.05 5,196 $244,471.80 1,036,681 SEC Form 4
Taylor Ian ARVN Chief Scientific Officer Feb 23 '24 Sell $47.05 1,701 $80,032.05 147,522 SEC Form 4
Peck Ronald ARVN Chief Medical Officer Feb 23 '24 Sell $47.05 1,699 $79,937.95 67,516 SEC Form 4

Share on Social Networks: